"EMA will now review all available data to assess whether this emerging information has an impact on the balance of benefits and risks of Tavneos," said the EU regulator. "The agency will then issue a ...

After an antitrust review knocked 2021’s biggest biopharma buyout off course in May, CSL’s $11.7 billion deal for Swiss iron deficiency specialist Vifor Pharma appears to be back on track. Tuesday, ...

Vifor, part of Australian group CSL, made the proposal following a two-year investigation by the European Commission. The EU competition enforcer was concerned by Vifor's allegedly misleading ...

Vifor Pharma has struck a deal to buy a priority review voucher (PRV). The PRV sets Vifor and partner Akebia Therapeutics up to benefit from a fast review at the FDA when they file for approval of ...

Promoting your product is fine, but not if it means throwing shade on competitors, according to the EU. The European Commission today accepted Vifor’s commitments to remedy potential disparagement of ...

ST. GALLEN, Switzerland--(BUSINESS WIRE)--Regulatory News: CSL Limited (ASX: CSL; USOTC:CSLLY) yesterday announced an update regarding the Vifor Pharma AG acquisition. CSL has previously advised that ...

Vifor Pharma has committed €25 million ($28 million) to a nephrology joint venture with Evotec. The initiative will see Evotec mine a kidney biobank for new renal therapy targets before the joint ...

ST. GALLEN, Switzerland & HAMBURG, Germany--(BUSINESS WIRE)--Regulatory News: Vifor Pharma and Evotec SE today announced the launch of a 50:50 joint venture focused on the discovery and development of ...

Vifor Pharma Group reported net sales of CHF 1,705.6 million, a decline of 1.1% compared to the previous year, or an increase of 3.7% at CER. The growth was impacted by COVID-19 restrictions which ...

The Sanifit deal is the bigger of the two transactions. Switzerland-based Vifor said Monday that it has agreed to pay €205 million (about $230.9 million) up front to acquire all of the shares in ...